LEXINGTON, Mass., Dec. 19, 2016 /PRNewswire/ -- Pulmatrix,
Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company
developing innovative inhaled therapies to address serious
pulmonary diseases, today announced that it has received five
patents over the last 12 months.
"These new patents are further proof that our
iSPERSE™ inhaled drug technology is innovative," said
Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix.
"These patents give us stronger composition of matter and method of
use intellectual property protection as we move forward to
develop drugs for COPD, fungal infections, and other
diseases."
Two of the patents (US 9,233,158 and US 9,238,005) extend
existing patent coverage in the United
States. Two more (JP 5,877,201 and JP 5,964,939) provide
similar extensions in Japan.
The fifth patent (US 9,433,576), which was granted on
September 6, 2016, broadens the
patent protection for Pulmatrix's innovative drug delivery
technology and its use to treat a wide variety of diseases.
As the patent explains, delivering drugs directly to the lungs
offers numerous advantages. But existing technologies have serious
limitations, such as leaving much of the drug stuck in the mouth or
throat, causing side effects. "Therefore, there remains a need for
the formation of small particle size aerosols that are highly
dispersible," the patent says.
Pulmatrix's technology seeks to meet that need. Its dry powder
'flies' easily into the lungs, reducing the amount stuck in the
throat. In addition, the technology can deliver much larger doses
of drugs—and many more different types of drugs—than existing
methods can.
The patent recognizes the advantages of the technology and
grants intellectual property protection for many different medical
uses of Pulmatrix's technology. As the patent states: "The
invention also relates to methods for treating a respiratory
disease, such as asthma, airway hyper-responsiveness, seasonal
allergic allergy, bronchiectasis, chronic bronchitis, emphysema,
chronic obstructive pulmonary disease, cystic fibrosis and the
like."
"As we look to continue to advance our pipeline, these patents
will prevent competitors from copying our technology," added Dr.
Clarke.
About
Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing
innovative inhaled therapies to address serious pulmonary disease
using its patented iSPERSE™ technology. The Company's proprietary
product pipeline is focused on advancing treatments for lung
diseases, including opportunities in major pulmonary diseases
through collaborations, like PUR0200, a branded generic in clinical
development for chronic obstructive pulmonary disease (COPD) and
PUR1900, an inhaled antifungal that could benefit severe asthmatics
and patients with rare disease like cystic fibrosis.
Pulmatrix's product candidates are based on iSPERSE™, its
proprietary dry powder delivery platform, which seeks to improve
therapeutic delivery to the lungs by maximizing local
concentrations and reducing systemic side effects to improve
patient outcomes.
FORWARD-LOOKING STATEMENTS
Certain statements in this
press release that are forward-looking and not statements of
historical fact are forward-looking statements within the meaning
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The Company cautions that such statements
involve risks and uncertainties that may materially affect the
Company's results of operations. Such forward-looking statements
are based on the beliefs of management as well as assumptions made
by and information currently available to management. Actual
results could differ materially from those contemplated by the
forward-looking statements as a result of certain factors,
including but not limited to the ability to establish that
potential products are efficacious or safe in preclinical or
clinical trials; the ability to establish or maintain
collaborations on the development of therapeutic candidates; the
ability to obtain appropriate or necessary governmental approvals
to market potential products; the ability to obtain future funding
for developmental products and working capital and to obtain such
funding on commercially reasonable terms; the Company's ability to
manufacture product candidates on a commercial scale or in
collaborations with third parties; changes in the size and nature
of competitors; the ability to retain key executives and
scientists; and the ability to secure and enforce legal rights
related to the Company's products, including patent protection. A
discussion of these and other factors, including risks and
uncertainties with respect to the Company, is set forth in the
Company's annual report on Form 10-K filed by the Company with the
Securities and Exchange Commission on March
10, 2016. The Company disclaims any intention or obligation
to revise any forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by
law.
Investor
Contact
Robert Clarke,
CEO
(781)
357-2333
rclarke@pulmatrix.com
William Duke, CFO
(781) 357-2333
wduke@pulmatrix.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/pulmatrix-receives-patents-important-to-its-inhaled-drug-delivery-technology-300380762.html
SOURCE Pulmatrix, Inc.